Ardelyx Pharma - רווח למניה ב-12 החודשים האחרונים ARDX

Ardelyx, Inc. (ARDX) is a defensive asset whose income is independent of macroeconomic conditions. Growth is driven by partnerships with global distributors to promote Xphozah. The annual EPS TTM trend captures the current trajectory, where the current value equals 4.80. Ardelyx, Inc. (ARDX) is implementing a unique therapy for cardiorenal pathologies by blocking specific intestinal receptors to treat kidney disease.
Ardelyx Corp - פילוחים אנליטיים ומדדי מפתח (ARDX)

This indicator measures the dynamics of net earnings per share over the last 12 months relative to the same period last year, capturing the business scaling rates. The current value of 4.80 reflects the financial impact of high physician and patient confidence following FDA approval, making the annual EPS growth rate over the last 12 months a key confirmation of the capitalization of Ardelyx, Inc. (ARDX) reputational success.